Company Overview
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
Why Investors Should Care
Generates a return on equity of 70.2%, reflecting efficient use of shareholder capital.
Revenue has grown at a 54.8% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $113.29M (+668.3% YoY); net profit $-351.40M.
- Trailing 12 Months Year-on-year growth — revenue +93.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 54.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 54.76% |
| 1 Year: | 93.90% |
Stock Price Performance
| 1 Year: | +186.52% |
| 6 Months: | -6.81% |
| 3 Months: | +16.76% |
| 1 Month: | +10.38% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)54.20 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 70.2%.
- Compounding revenue at 54.8% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 30.0% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IBRX ImmunityBio, Inc. R2KR3KPHARMA | 8.08 | -8.51 | $8.56B | 0.00% | -58.17% | 70.21% | 54.76% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 41.00K | 82.00K | 40.00K | 1.05M | 6.11M | 16.52M | 26.43M | 32.06M | 44.21M | 51.24M |
| Operating Income | -130.40M | -46.46M | -29.92M | -31.62M | -34.97M | -32.77M | -25.14M | -25.46M | -23.82M | -24.44M | -25.39M | -28.28M | -28.28M | -24.11M | -17.72M | -18.34M | -17.30M | -16.07M | -16.11M | -36.70M | -50.92M | -65.88M | -30.89M | -86.26M | -85.91M | -78.84M | -95.97M | -79.62M | -90.80M | -111.58M | -85.14M | -80.14M | -95.20M | -99.33M | -80.25M | -64.43M | -71.28M | -55.63M | -69.79M | -61.70M |
| Net Income | -130.89M | -46.31M | -26.82M | -30.68M | -34.00M | -31.90M | -24.24M | -24.52M | -23.45M | -23.97M | -24.49M | -27.52M | -27.73M | -23.64M | -17.34M | -17.89M | -16.68M | -15.58M | -15.64M | -37.04M | -51.44M | -65.60M | -32.13M | -79.61M | -88.29M | -87.63M | -102.83M | -94.59M | -110.94M | -116.34M | -137.88M | -95.58M | -134.11M | -134.56M | -85.73M | -129.65M | -92.56M | -67.25M | -632.78M | -230.38M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.17 | - | -0.21 | -0.23 | -0.22 | -0.26 | -0.24 | -0.28 | -0.27 | -0.32 | -0.19 | -0.20 | -0.20 | -0.14 | -0.15 | -0.10 | -0.07 | -0.62 | -0.22 |
| R&D Expense | 2.07M | 4.66M | - | 4.96M | 6.39M | 8.36M | - | 9.25M | 9.71M | 11.07M | - | 13.99M | 14.69M | 14.56M | - | 12.60M | 13.13M | 12.05M | - | 27.37M | 33.01M | 35.77M | - | 41.13M | 53.80M | 49.28M | 55.38M | 63.08M | 71.61M | 79.26M | 53.17M | 48.40M | 53.35M | 51.13M | 50.44M | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 600.00K | 641.00K | 236.00K | 44.00K | 45.00K | 47.00K | 2.20M | 605.00K | 934.00K | 240.00K | 622.00K | 14.74M | 113.29M |
| Operating Income | - | -5.58M | -238.88M | -124.50M | -99.12M | -98.39M | -156.25M | -220.88M | -330.28M | -351.30M | -362.25M | -344.18M | -256.03M |
| Net Income | -2.05M | -6.18M | -236.88M | -120.81M | -96.42M | -96.23M | -157.78M | -221.85M | -346.79M | -416.57M | -583.20M | -413.56M | -351.40M |
| Diluted EPS | - | - | - | - | - | - | -0.43 | -0.59 | -0.89 | -1.04 | -1.15 | -0.62 | -0.38 |
| R&D Expense | 446.00K | 1.59M | 11.43M | 29.15M | 42.04M | 55.72M | 112.00M | 139.51M | 195.96M | 248.15M | 232.37M | 190.14M | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 366.85M | 317.50M | 250.44M | 181.95M | 143.12M | 221.38M | 468.91M | 362.36M | 504.45M | 382.93M | 501.90M |
| Total Equity | - | -3.75M | 57.59M | 356.00M | 293.42M | 218.84M | 146.01M | 120.68M | -119.81M | -242.17M | -447.33M | -586.99M | -489.10M | -500.47M |
| Cash & Equivalents | 116.00K | 350.00K | 59.10M | 175.91M | 8.08M | 23.87M | 16.82M | 75.80M | 34.91M | 181.10M | 104.64M | 265.45M | 143.43M | 88.33M |
| Total Liabilities | - | - | - | 10.85M | 24.08M | 31.60M | 35.94M | 22.44M | 339.87M | 712.82M | 812.18M | 1.09B | 871.06M | 1.00B |
| Current Liabilities | - | - | 1.88M | 6.15M | 12.55M | 20.87M | 27.26M | 11.56M | 68.13M | 369.00M | 500.86M | 58.28M | 54.94M | 61.75M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -38.59M | -48.78M | -63.38M | -152.11M | -171.72M | - | -337.51M | -366.76M | -391.24M | -304.94M |
| Investing Cash Flow | - | - | - | -113.67M | 99.55M | 57.10M | 18.55M | -19.81M | - | 27.30M | -30.47M | -12.25M | -149.80M |
| Financing Cash Flow | - | - | - | -15.56M | -34.98M | -771.00K | 114.28M | 150.68M | - | 233.61M | 558.34M | 281.63M | 400.24M |
| Capital Expenditure | -3.00K | -235.00K | -2.24M | -6.56M | -34.81M | -13.10M | -4.29M | -1.67M | - | -99.39M | -30.58M | -6.89M | -4.25M |
| Free Cash Flow | - | - | - | -45.15M | -83.59M | -76.48M | -156.40M | -173.39M | - | -436.90M | -397.34M | -398.12M | -309.19M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | -76.60M | 161.11M | -121.85M | -54.50M |
| Share Buybacks | - | 0 | 4.80M | 15.85M | 15.23M | 228.00K | 2.50M | 0 | 0 | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -869.7% | -101,218.6% | -282,954.5% | -220,266.7% | -209,338.3% | -7,095.9% | -36,509.1% | -35,361.9% | -146,374.2% | -58,239.5% | -2,334.2% | -226.0% |
| Net Margin % | -341.2% | -964.9% | -100,371.2% | -274,565.9% | -214,273.3% | -204,736.2% | -7,165.2% | -36,669.6% | -37,129.6% | -173,569.6% | -93,761.4% | -2,804.8% | -310.2% |
| ROE % | 54.5% | -10.7% | -66.5% | -41.2% | -44.1% | -65.9% | -130.7% | 185.2% | 143.2% | 93.1% | 99.4% | 84.6% | 70.2% |
| ROCE % | - | - | -66.2% | -40.8% | -43.2% | -63.6% | -118.8% | -144.1% | -330.6% | 253.6% | -81.2% | -104.9% | -58.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 3.22% | 34.08M | $274.37M |
| 2 | State Street Corporation | 2.02% | 21.40M | $172.26M |
| 3 | Vanguard Portfolio Management LLC | 1.69% | 17.86M | $143.80M |
| 4 | Vanguard Capital Management LLC | 1.48% | 15.69M | $126.32M |
| 5 | Shaw D.E. & Co., Inc. | 1.09% | 11.55M | $92.99M |
| 6 | Two Sigma Investments, LP | 1.05% | 11.10M | $89.33M |
| 7 | Geode Capital Management, LLC | 0.93% | 9.85M | $79.28M |
| 8 | Millennium Management Llc | 0.53% | 5.58M | $44.92M |
| 9 | Northern Trust Corporation | 0.34% | 3.57M | $28.70M |
| 10 | Morgan Stanley | 0.32% | 3.43M | $27.63M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IBRX
IBRX Stock Climbs After-Hours: Retail Traders Bet Russell 1000 Inclusion Could Trigger Massive Index-Fund Buying - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQdU1CUXkwM0tIRUFpNFRKbHVUY0cyTHp0c3MyT0VzajJBWVVENXRpTXVta2RiRTFlWmFoT3E1MTZwT3dlUjR4cDFTTzhWX0VnYjIyS01BbGE0OVdSZU9hQjBvOEM5M0R5VFhZNko3R2tXRXVjcnJWMTg3UGEtWUo1M29Rdml3dlpldGk4U3…
ImmunityBio (IBRX) Shares Moved, What Is Behind The Fresh Attention? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxQYm9SN2loTW9WZnNwNU5XaXNmVmFVb0R0YWVLcUVMVk9pWVRTREd3WHpNUWFkblloNnBMa2FTQlk5VjhQNTJ5RnNkOUFNeEs4RUg0aW1nLXBjQjFBY0JVRmtFNUtUMXVQQVZ6a1NjZElCOWpyZUhhUE1iU3Raa2QwRU1OSVllOXVSWDhmWm…
IBRX Stock Jumps Overnight: UAE Grants Anktiva Broadest Approval Yet After Founder’s ‘July Birthday News’ Tease - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxOeFdTNWdQeWdmbl9VdjYtd2huLVV0M2lPZ0FUSGJuUlAycm4zMl92Skg4eWJMWTlQb203SXoyR3JscTVsWTYtWHNNWms3UzlRNGNZMzJTa0o5U0NkR3Y5bWxYOXEzYjBOLWtHUzluU0JaeHNsT0pxUXkxeDZLQWhuQ0dZZlhXaVRHMFVEcn…
ImmunityBio (IBRX) Stock Looks Rich On Sales But Strong On Returns - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNSVZSWmUzb0NiYk9oZE84azJCc0JFYXgxVVhNR1o2QnVRdEwtNGtqLWlidG9JVDI2cDBZU0phTUtZSEVLbXYwcEFDTURJSVgwdjROSENxNmx6SWtleXhMcDhTU25xTXJDa0hTWDdxem9VaGhqMzB1T3JJSmdHbTlrSWk4N0ZIcDc2WjliS2…
How IBRX Company (IBRX) Affects Rotational Strategy Timing - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPOVhCXzdidnhSNFdOLWgwX1B4R2o2QnRrSVJGRXlMYklPc2ZreFltN1dMV0pqdVQ0MjRaOTd4cHpSd3luaW1qajAwV1BGUGZTcFYtWS1MUTRHby1ib21tQUhhZ0dPaVJBX1BtZF96N3J4S3RsVEs3LThWeFZFRFZieEpZMUhSNlZBQ2J1Vk…
IBRX Stock Outlook After Q1 Results and a New FDA Review - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOOWFvQlVvVlBfMVVaN3NsbG1oc3NpM0JfWU8zVGFnckpBRkFzVGh4eXdOUnlENHJFdWJnT1dVczNOMmcxNHJINjY2Njc0VzhUQmpWZEk5NHA1T1d5cUJSMUxabGRUMzlNZ1lVbUViaWxFN20zbVNxbnpKVFZQNF9lVk5qTmZ0TlA5bHl3Q0…
IBRX — Frequently Asked Questions
What is the current share price of ImmunityBio, Inc. (IBRX)?
As of 2026-09-07 16:24 PDT, ImmunityBio, Inc. (IBRX) trades at $8.08 on NasdaqGS. Its 52-week range is $1.98 to $11.55.
What is the market capitalisation of IBRX?
ImmunityBio, Inc. (IBRX) has a market capitalisation of $8.56B on NasdaqGS.
What is the P/E ratio of IBRX?
IBRX trades at a trailing price-to-earnings (P/E) ratio of -8.51. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -7.62.
What is the return on equity (ROE) of IBRX?
IBRX has a return on equity (ROE) of 70.21%. Its return on capital employed (ROCE) is -58.17%.
Is IBRX a good stock to buy?
This page provides a data-driven analysis of ImmunityBio, Inc. (IBRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.